 
 |
|
Pine Rest expands research
Date: March 29, 2010
Client: AssureRx Health, Inc.
Summary: Pine Rest Christian Mental Health Services is embarking on a study that represents the first step in boosting its clinical research efforts as part of Grand Rapids’ growing medical research community.
|
|
|
|
 |
|
Genetic test could match mentally ill patients with the best drug
Date: March 27, 2010
Client: AssureRx Health, Inc.
Summary: A genetic test that predicts how patients with mental illnesses such as depression and schizophrenia will respond to drugs is to be offered to British doctors, in a step towards a new era of personalised medicine.
|
|
|
|
 |
|
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of APD916 for Narcolepsy and Cataplexy
Date: March 24, 2010
Client: Arena Pharmaceuticals
Summary: SAN DIEGO, March 24, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy and cataplexy.
|
|
|
|
 |
|
Celladon Corporation Receives Notice of Allowance by U.S. Patent and Trademark Office for Broad Patent Covering Lead Drug Candidate MYDICAR®
Date: March 23, 2010
Client: Celladon Corporation
Summary: LA JOLLA, Calif., March 23, 2010 – Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent covering the company’s lead drug candidate MYDICAR®, a genetically targeted enzyme replacement therapy for advanced heart failure. The patent will be issued to The Regents of the University of California and licensed exclusively to Celladon.
|
|
|
|
 |
|
febit Launches Whole Genome Sequencing Service in Europe
Date: March 22, 2010
Client: febit
Summary: LEXINGTON, Mass. (USA), and HEIDELBERG, Germany, March 22, 2010 – febit today announced that the company now offers whole genome sequencing services in Europe for a broad range of species. febit is known for its reliable and accurate targeted resequencing services and instruments for genome exploration.
|
|
|
|
 |
|
Helix BioPharma Corp Achieves Last-Patient-Out in Its Phase II Trial of Topical Interferon Alpha-2b in Patients with Ano-Genital Warts
Date: March 22, 2010
Client: Helix BioPharma Corp
Summary: AURORA, Ontario, March 22 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) announced today that it has achieved last-patient-out in its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW). Accordingly, all patients enrolled in the study have completed the prescribed study procedures, and Helix will now proceed to closing of the database and analysis of the results. Based on the trial design and schedule, final reporting is expected in mid to late calendar 2010, as previously announced.
|
|
|
|
 |
|
Clarus Ventures Names William D. Young Venture Partner
Date: March 22, 2010
Client: Clarus Ventures
Summary: Cambridge, Mass. and San Francisco, March 22 /PRNewswire/ -- Clarus Ventures, LLC ("Clarus"), a global life sciences venture capital firm, today announced that William D. Young has joined the firm as a venture partner at its San Francisco office.
|
|
|
|
|
|
Arena Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
Date: March 18, 2010
Client: Arena Pharmaceuticals
Summary: SAN DIEGO, March 18, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, March 23, 2010, at 5:15 p.m. Eastern Time (2:15 p.m. Pacific Time) at the Loews Miami Beach Hotel in Miami, Florida. Cindy McGee, Arena's Manager of Investor Relations and Corporate Communications, is scheduled to provide an overview of the company, including its clinical development and research programs.
|
|
|
|
 |
|
Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeich's Genous™ Bio-engineered R stent™
Date: March 17, 2010
Client: OrbusNeich
Summary: ATLANTA, March 17, 2010 – OrbusNeich today announced that 12 month follow up data from real world patients demonstrated long term clinical efficacy of the company’s Genous Bio-engineered R stent.
|
|
|
|
 |
|
Arena will launch lorcaserin with partner or alone
Date: March 12, 2010
Client: Arena Pharmaceuticals
Summary: LOS ANGELES, March 12 (Reuters) - Arena Pharmaceuticals Inc (ARNA.O) expects to launch sales of its weight loss drug -- alone or with a partner -- within 12 weeks of U.S. regulatory approval, according to the company.
|
|
|
|
 |
|
CDI Launching iPS Cells For Screening
Date: March 11, 2010
Client: Cellular Dynmaics International
Summary: Cellular Dynamics International is announcing the launch of the first human cells derived from induced pluripotent stem cells (iPSCs) for use in screening new drug candidates for drug toxicity and for drug discovery. iCell Cardiomyocytes mimic the biochemical and electrophysiological activity of normal human heart muscle cells.
|
|
|
|
 |
|
Cempra Announces the Completion of Phase 1 Studies for CEM-101, a Next-Generation Macrolide
Date: March 10, 2010
Client: Cempra Pharmaceuticals
Summary: CHAPEL HILL, N.C, March. 10, 2010 – Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study with the company’s intravenous formulation of CEM-101 in mid-2010.
|
|
|
|
|
|
Arena Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference
Date: March 8, 2010
Client: Arena Pharmaceuticals
Summary: SAN DIEGO, March 8, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq:ARNA - News) announced today that the company is scheduled to present at the Cowen and Company 30th Annual Health Care Conference on Wednesday, March 10, 2010, at 8:45 a.m. Eastern Time (5:45 a.m. Pacific Time) at the Boston Marriott Copley Place in Boston, Massachusetts. Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer, is scheduled to provide an overview of the company, including its clinical development and research programs.
|
|
|
|
 |
|
Afraxis Appoints Chief Scientific Officer and Vice President, Corporate Development
Date: March 8, 2010
Client: Afraxis
Summary: SAN DIEGO, March 8 /PRNewswire/ -- Afraxis, a San Diego-based biotechnology company developing drugs to treat central nervous system (CNS) disorders, today announced the appointment of David Campbell, Ph.D., as chief scientific officer and Carmine Stengone as vice president, corporate development.
|
|
|
|
 |
|
AssureRx Adds Fifth Gene to Pharmacogenetic Profile to Guide Psychiatric Drug Prescribing
Date: March 8, 2010
Client: AssureRx Health, Inc.
Summary: CINCINNATI, March 8, 2010 – AssureRx Health, Inc., a personalized medicine company focused on pharmacogenetics to aid in the treatment of patients with psychiatric disorders, today announced that it has added a fifth gene, CYP1A2, to its laboratory-developed pharmacogenetic test. GeneSightRx® measures and analyzes more than forty clinically important genetic variants that affect patients’ response to medications prescribed in psychiatric medicine. The CYP1A2 gene is involved in the metabolism of a number of commonly used drugs, including antidepressants and antipsychotics.
|
|
|
|
|
|
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 12, 2010
Date: March 8, 2010
Client: Arena Pharmaceuticals
Summary: SAN DIEGO, March 8, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report fourth quarter and full year 2009 financial results before the NASDAQ Global Market opens on Friday, March 12, 2010. That same morning, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, will host a conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results for the fourth quarter and full year 2009 and to provide a business and financial update.
|
|
|
|
 |
|
Security Health Plan Signs With MedAssurant to Improve Care Management
Date: March 4, 2010
Client: MedAssurant, Inc.
Summary: BOWIE, Maryland and MARSHFIELD, Wisconsin – March 4, 2010 – MedAssurant, Inc., a leading provider of data-driven healthcare solutions, announced today that Security Health Plan, a health maintenance organization serving more than 182,000 residents of Wisconsin, including nearly 80,000 Medicare and Medicaid members, has implemented MedAssurant’s SmartCare™ suite of care management solutions to support its ongoing focus on member clinical quality outcomes and financial efficiency.
|
|
|
|
|
|
Cempra Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference
Date: March 4, 2010
Client: Cempra Pharmaceuticals
Summary: CHAPEL HILL, N.C., March 4 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Cowen and Company 30th Annual Health Care Conference at 3 p.m. EST, March 8, 2010, at The Boston Marriott Copley Place in Boston. Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, CEM-101 for community-acquired bacterial pneumonia and TAKSTA™ for the oral treatment of gram positive pathogens including MRSA.
|
|
|
|
 |
|
Cellular Dynamics and Roche Conduct 'Stem Cells in Drug Discovery and Development' Workshop at the Society of Toxicology Annual Meeting
Date: March 2, 2010
Client: Cellular Dynamics International
Summary: MADISON, Wis., March 2 /PRNewswire/ -- Cellular Dynamics International (CDI) and Hoffmann-La Roche Inc. (Roche) today announced a workshop to be held during the Society of Toxicology Annual Meeting in Salt Lake City, UT, on March 7 - 11.
|
|
|
|
 |
|
Targeted Resequencing Improves Precision
Date: March 1, 2010
Client: febit
Summary: Next month in San Diego, CHI will present “Now Generation Sequencing” in which discussions about targeted resequencing will be front and center. This mixture of molecular biology and sophisticated computer analysis hones in on genomic regions of interest, interrogating multiple genetic sites. Enabling the detection of rare mutations and hard-to-reach corners of the genome, it takes advantage of low sample-input requirements. Moreover, these strategies allow areas of interest to be identified through genome-wide association studies while sequencing genes and candidate regions.
|
|
|
|
|
|
febit’s miRBase 14 Geniom-Biochip Now With 58 Additional New Sequences Available for Cancer Research
Date: March 1, 2010
Client: febit
Summary: LEXINGTON, Mass. (USA), and HEIDELBERG, Germany, March 01, 2010 – febit today announced that an updated version of the company’s Geniom Biochip containing 58 new discovered sequences in addition to all of the Homo sapiens microRNAs (miRNA) from miRBase version 14 (www.mirbase.org) is now available for cancer research. The 58 new miRNA sequences were found by deep sequencing in a miRNA discovery study performed on an Applied Biosystems SOLiD 3 sequencing system. All 58 miRNAs have been validated using the ABI TaqMan miRNA qRT-PCR assay and are now available for further studies using febit’s microarray technology for miRNA-profiling.
|
|
|
|
|
